-
Exploring the role of disulfidptosis-related signatures in immune microenvironment, prognosis and therapeutic strategies of cervical cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-03-15 Tianzhe Jin, Taotao Yin, Ruiyi Xu, Hong Liu, Shuo Yuan, Yite Xue, Jianwei Zhang, Hui Wang
Cervical cancer is characterized by a complex immunosuppressive tumor microenvironment (TME). Disulfidptosis is a recently identified form of programmed cell death that has emerged as a crucial factor in tumorigenesis. However, the research on the specific involvement of disulfidptosis within the TME is still in its early stages. Under glucose starvation, SiHa and HeLa cells underwent experiments employing
-
Insights into the role of the N6-methyladenosine reader IGF2BP3 in the progression of oral squamous cell carcinoma and its connection to cell-cycle control Transl. Oncol. (IF 5.0) Pub Date : 2024-03-15 Dandan Song, Xiaofeng Dai, Minna Fu, Yang Sun, Xingwen Wu, Qianrong Zhou, Wei Bi, Jian Sun, Fei Yang, Youcheng Yu
The genome of oral squamous cell carcinoma (OSCC) has been extensively characterized via bulk sequencing, revealing a multitude of genetic changes. The gene IGF2BP3, which encodes for the insulin-like growth factor 2 mRNA-binding protein 3, has been observed to be highly expressed in several types of cancer. This finding suggests that IGF2BP3 may play a significant role in the initiation and advancement
-
Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-03-15 Luis E. Velázquez-Vega, Michael Rivera-Robles, Annelis O. Sánchez-Álvarez, Pablo E. Vivas-Mejía, Miciely Aponte-Reyes, Ailed M. Cruz-Collazo, Nilmary Grafals-Ruiz, Stephanie Dorta-Estremera, Eliud Hernández-O'Farrill, Cornelis P Vlaar, Suranganie Dharmawardhane
Trastuzumab and trastuzumab-based treatments are the standard of care for breast cancer patients who overexpress the human epidermal growth factor receptor 2 (HER2). However, patients often develop resistance to trastuzumab via signaling from alternative growth factor receptors that converge to activate guanine nucleotide exchange factors (GEFs) that in turn activate the Rho GTPases Rac and Cdc42.
-
Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells Transl. Oncol. (IF 5.0) Pub Date : 2024-03-14 Yifat Koren Carmi, Abed Agbarya, Hazem Khamaisi, Raymond Farah, Yelena Shechtman, Roman Korobochka, Jacob Gopas, Jamal Mahajna
Ovarian cancer (OC), the second most common form of gynecologic malignancy, has a poor prognosis and is often discovered in the late stages. Platinum-based chemotherapy is the first line of therapy. Nevertheless, treatment OC has proven challenging due to toxicity and the development of acquired resistance to therapy. Tumor microenvironment (TME) has been associated with platinum chemoresistance.
-
Single-cell sequencing revealed metabolic reprogramming and its transcription factor regulatory network in prostate cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-03-06 Guojiang Wei, Hongcai Zhu, Yupeng Zhou, Yang Pan, Bocun Yi, Yangkai Bai
[Display omitted]
-
CCR7 affects the tumor microenvironment by regulating the activation of naïve CD8+ T cells to promote the proliferation of oral squamous cell carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-03-02 Cong Yan, Weidong Du, Keith L. Kirkwood, Yao Wang, Wanhang Zhou, Zhenning Li, Yuan Tian, Shanfeng Lin, Li Zheng, Maged Ali Al-Aroomi, Jiaxing Gao, Sheng Jiang, Changfu Sun, Fayu Liu
Head and neck cancer is the sixth most common malignancy worldwide, and oral squamous cell carcinoma (OSCC) is the most common head and neck cancer, being one of the leading causes of cancer morbidity and mortality worldwide. CC Chemokine receptor 7(CCR7) is a multifunctional G protein-coupled trans-membrane chemokine that affects immune cell chemotaxis, migration, and cancer progression through its
-
Genomic profiles and their relationships with clinical characteristics and immune features in cervical cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-03-02 Zinan Lu, Peiwen Fan, Wen Huo, Yaning Feng, Ruozheng Wang
This study aimed to investigate the genomic alteration profiles of cervical cancer patients, examine the correlation between mutation patterns and clinical and immune attributes, and discover novel targets for treatment of individuals with cervical cancer. We performed targeted next-generation sequencing of tumor tissues and blood samples obtained from 45 cervical cancer patients to analyze somatic
-
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial Transl. Oncol. (IF 5.0) Pub Date : 2024-02-27 Bonnita Werner, Katrin M Sjoquist, David Espinoza, Sonia Yip, Garry Chang, Michelle M Cummins, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Michael Friedlander, Kristina Warton, Caroline E. Ford
To investigate cell-free DNA (cfDNA) in plasma and ascites and its association with clinical outcomes (paracentesis-free interval, overall survival) and CA125 level in participants with advanced ovarian cancer, treated with palliative intraperitoneal bevacizumab to delay re-accumulation of ascites. cfDNA was extracted from 0.3 to 1 mL samples from 20/24 participants of the REZOLVE trial. Standard and
-
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition Transl. Oncol. (IF 5.0) Pub Date : 2024-02-27 Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti
Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly selective Phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib (IOA-244) on MPM cells and on the immune cells in MPM microenvironment.
-
Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment Transl. Oncol. (IF 5.0) Pub Date : 2024-02-27 Yucheng Dong, Zhizhuo Chen, Fan Yang, Jiaxin Wei, Jiuzuo Huang, Xiao Long
Immune checkpoint inhibitors (ICB) therapy have emerged as effective treatments for melanomas. However, the response of melanoma patients to ICB has been highly heterogenous. Here, by analyzing integrated scRNA-seq datasets from melanoma patients, we revealed significant differences in the TiME composition between ICB-resistant and responsive tissues, with resistant or responsive tissues characterized
-
XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant Transl. Oncol. (IF 5.0) Pub Date : 2024-02-27 Christophe Van Berckelaer, Steven Van Laere, Seayoung Lee, Michael A Morse, Joseph Geradts, Luc Dirix, Mark Kockx, François Bertucci, Peter Van Dam, Gayathri R Devi
To assess the expression pattern of X-linked inhibitor of apoptosis protein (XIAP), a cellular stress sensor, and delineate the associated changes in the tumor immune microenvironment (TiME) for prognostic value and new therapeutic targets in inflammatory breast cancer (IBC). Immunohistochemistry was conducted to assess the spatial localization of immune subsets, XIAP, and PDL1 expression in IBC and
-
Loss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-02-27 Shreya Sharma, Harsha Rani, Yeshwanth Mahesh, Mohit Kumar Jolly, Jagannath Dixit, Vijayalakshmi Mahadevan
Wild type p53 binding sites are associated with promoters of SATB1 and with the loss of p53, these promoters are occupied by repressive histone marks H3K27me3 correlating with decreased expression of SATB1 (unpublished work from the lab). Expression of SATB1 antagonistically relates with EZH2 which correlates with our findings. Upon EMT induction with TGF-β treatment, the expression of SATB1 increases
-
Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia Transl. Oncol. (IF 5.0) Pub Date : 2024-02-26 Soumika Sengupta, Mainak Biswas, Khushboo A. Gandhi, Saurabh Kumar Gupta, Poonam B. Gera, Vikram Gota, Avinash Sonawane
[Display omitted]
-
Comprehensive analysis and experimental verification of the mechanism of action of T cell-mediated tumor-killing related genes in Colon adenocarcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-26 Jing Chen, Zhengfang Wang, Qin Zhu, Shiqi Ren, Yanhua Xu, Guangzhou Wang, Lin Zhou
Colorectal cancer (CRC) is a prevalent malignancy of the digestive tract. A new prognostic scoring model for colon adenocarcinoma (COAD) is developed in this study based on the genes involved in tumor cell-mediated killing of T cells (GSTTKs), accurately stratifying COAD patients, thus improving the current status of personalized treatment. The GEO and TCGA databases served as the sources of the data
-
Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients Transl. Oncol. (IF 5.0) Pub Date : 2024-02-24 Qiang Li, Meng Jiang, Shiqiang Hong, Jing Yang, Xiaoying Wu, Jiaohui Pang, Yedan Chen, Xiaotian Zhao, Xiao Ding
Lung adenocarcinoma is the most common source of brain metastasis (BM), resulting in significant morbidity and mortality. We aimed to identify patients with high BM risk who possibly benefit from brain-penetrant drugs, prophylactic cranial irradiation, or close brain magnetic resonance imaging surveillance. Metastatic lung adenocarcinoma patients with extracranial tumor samples profiled by a next-generation
-
CT-guided high dose rate brachytherapy can induce multiple systemic proteins of proliferation and angiogenesis predicting outcome in HCC Transl. Oncol. (IF 5.0) Pub Date : 2024-02-23 Lukas Salvermoser, Shraga Nahum Goldberg, Marianna Alunni-Fabbroni, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Jan Niklas Schäfer, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Agnese Petrera, Moritz Wildgruber, Jens Ricke, Matthias Stechele
To determine the potential prognostic value of proliferation and angiogenesis plasma proteins following CT-guided high dose rate brachytherapy (HDR-BT) of hepatocellular carcinoma (HCC). For this prospective study, HDR-BT (1 × 15 Gy) was administered to 24 HCC patients. Plasma was obtained and analyzed using an Olink proteomics Target-96 immuno-oncology-panel that included multiple markers of angiogenesis
-
Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-22 Deepti Singh, Mohammad Afsar Khan, Dhruv Mishra, Aditya Goel, Mairaj Ahmed Ansari, Kafil Akhtar, Hifzur R. Siddique
[Display omitted]
-
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-22 Xu Chen, Bo Sun, Yu Chen, Yili Xiao, Yinghui Song, Sulai Liu, Chuang Peng
Cholangiocarcinoma is a kind of epithelial cell malignancy with high mortality. Intratumor heterogeneity (ITH) is involved in tumor progression, aggressiveness, treatment resistance, and disease recurrence. Integrative machine learning procedure including 10 methods (random survival forest, elastic network, Lasso, Ridge, stepwise Cox, CoxBoost, partial least squares regression for Cox, supervised principal
-
Genetic testing for hereditary cancer syndromes in Tunisian patients: Impact on health system Transl. Oncol. (IF 5.0) Pub Date : 2024-02-21 Nouha Jandoubi, Maroua Boujemaa, Najah Mighri, Nesrine Mejri, Sonia Ben Nasr, Hanen Bouaziz, Yosra Berrazega, Haifa Rachdi, Nouha Daoud, Aref Zribi, Jihene Ayari, Houda El Benna, Soumaya Labidi, Abderazzek Haddaoui, Ridha Mrad, Slim Ben Ahmed, Hamouda Boussen, Sonia Abdelhak, Samir Boubaker, Yosr Hamdi
[Display omitted]
-
Multi-omics analysis-based macrophage differentiation-associated papillary thyroid cancer patient classifier Transl. Oncol. (IF 5.0) Pub Date : 2024-02-20 Hanlin Sun, Zhengyan Chang, Hongqiang Li, Yifeng Tang, Yihao Liu, Lixue Qiao, Guicheng Feng, Runzhi Huang, Dongyan Han, De-tao Yin
The reclassification of Papillary Thyroid Carcinoma (PTC) is an area of research that warrants attention. The connection between thyroid cancer, inflammation, and immune responses necessitates considering the mechanisms of differential prognosis of thyroid tumors from an immunological perspective. Given the high adaptability of macrophages to environmental stimuli, focusing on the differentiation characteristics
-
Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis Transl. Oncol. (IF 5.0) Pub Date : 2024-02-19 Peijie Lei, Lianjing Cao, Hongjun Zhang, Jialei Fu, Xiaojuan Wei, Fei Zhou, Jingjing Cheng, Jie Ming, Haijun Lu, Tao Jiang
Oxaliplatin (OXA)-based chemotherapy is one of the first-line treatments for advanced gastric cancer. However, the potential risk for chemotherapy-induced hepatic injury can hinder its effectiveness. Polyene phosphatidylcholine (PPC) is often used as a hepatoprotective agent to counter OXA-induced hepatic injury; however, its impact on the antitumour effectiveness of OXA remains uncertain. Our retrospective
-
Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis Transl. Oncol. (IF 5.0) Pub Date : 2024-02-19 Dandan Ding, Chenguang Xu, Jufeng Zhang, Ying Zhang, Lipeng Xue, Jingjing Song, Zhiming Luo, Xiaoyu Hong, Jian Wang, Weicheng Liang, Xingyang Xue
Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the preferred treatment for EGFR-mutated lung cancer. However, acquired resistance inevitably develops. While non-coding RNAs have been implicated in lung cancer through various functions, the molecular mechanisms responsible for osimertinib resistance remain incompletely elucidated. RNA-sequencing
-
Graphene therapy-related lncRNAs as prognostic and immune microenvironmental biomarkers in hepatocellular carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-17 Weilong Ye, Hui Li, Juan Zhao, Deshuai Lu, Tao Tao, Xiao Zhu
[Display omitted]
-
HNRNPL facilitates ferroptosis in hepatocellular carcinoma cells by promoting S100A9 expression Transl. Oncol. (IF 5.0) Pub Date : 2024-02-17 Lanfang Yang, Zhibo Zhang, Xiangqing Yao, Xukun Wu, Zhao Zhang
This study probed into the effect of HNRNPL on ferroptosis in hepatocellular carcinoma (HCC) cells and related molecular mechanisms. Expression patterns of HNRNPL, Recombinant S100 Calcium Binding Protein A9 (S100A9) were analyzed in HCC tissues or cells. Following transfection, HCC cell activity was analyzed, followed by detection of levels of ROS, iron content, LPO, MDA, and GSH as well as the expression
-
Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-02-14 Magdalena Bojko, Katarzyna Węgrzyn, Emilia Sikorska, Piotr Ciura, Claire Battin, Peter Steinberger, Katarzyna Magiera-Mularz, Grzegorz Dubin, Adam Kulesza, Adam K. Sieradzan, Marta Spodzieja, Sylwia Rodziewicz-Motowidło
[Display omitted]
-
Tenascin-C as a potential biomarker and therapeutic target for esophageal squamous cell carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-14 Yang Liu, Li-Yan Yang, Ding-Xiong Chen, Chen Chang, Qing Yuan, Yu Zhang, Yan Cai, Wen-Qiang Wei, Jia-Jie Hao, Ming-Rong Wang
To establish a prognostic model of esophageal squamous cell carcinoma (ESCC) patients based on tenascin-C (TNC) expression level and clinicopathological characteristics, and to explore the therapeutic potential of TNC inhibition. The expression of TNC was detected using immunohistochemistry (IHC) in 326 ESCC specimens and 50 normal esophageal tissues. Prognostic factors were determined by Cox regression
-
Up-regulation of MIC19 promotes growth and metastasis of hepatocellular carcinoma by activating ROS/NF-κB signaling Transl. Oncol. (IF 5.0) Pub Date : 2024-02-13 Zhanbing Meng, Shixia Cheng, Weifang Wang, Zhouxia Wei, Zheng Guo, Xuying Zhao, Bing Wu, Hulin Chang, Nan Wang
Mitochondrial malfunction has been well-recognized as a critical step in the pathogenesis of many types of diseases, including cancer. MIC19 is a core a subunit of the MICOS complex that plays a critical role in maintaining the normal function of mitochondria. However, the biological functions of MIC19 in human hepatocellular carcinoma (HCC) remain unclear. The expression level of MIC19 in HCC was
-
RNA-binding protein IGF2BP2 suppresses metastasis of clear cell renal cell carcinoma by enhancing CKB mRNA stability and expression Transl. Oncol. (IF 5.0) Pub Date : 2024-02-10 Junwu Ren, Bo Huang, Wei Li, Yongquan Wang, Xiaojuan Pan, Qiang Ma, Yuying Liu, Xiaolin Wang, Ce Liang, Yuying Zhang, Shimin Wang, Feifei Yang, Haiping Li, Hao Ning, Yan Jiang, Changhong Qin, Ai Ran, Bin Xiao
Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer, with a highly aggressive phenotype and poor prognosis. RNA binding proteins (RBPs) play crucial roles in post-transcriptional gene regulation and have been implicated in tumorigenesis. RBPs have the potential to become a new therapeutic target for ccRCC. In this study, we screened and validated that insulin-like growth factor
-
Insights into molecular mechanisms of chemotherapy resistance in cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-02-10 Animesh Kar, Shivam Agarwal, Agrata Singh, Avinash Bajaj, Ujjaini Dasgupta
[Display omitted]
-
Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients Transl. Oncol. (IF 5.0) Pub Date : 2024-02-09 Arthur Daban, Ludivine Beaussire-Trouvay, Émilie Lévêque, Cristina Alexandru, Isabelle Tennevet, Olivier Langlois, Ovidiu Veresezan, Florent Marguet, Florian Clatot, Frédéric Di Fiore, Nasrin Sarafan-Vasseur, Maxime Fontanilles
Liquid biopsy application is still challenging in glioblastoma patients and the usefulness of short-length DNA (slDNA) fragments is not established. The aim was to investigate slDNA concentration as a prognostic marker in unresected glioblastoma patients. Patients with unresected glioblastoma and treated by radiochemotherapy (RT/TMZ) were included. Plasmas were prospectively collected at three times:
-
Mitochondria-related chemoradiotherapy resistance genes-based machine learning model associated with immune cell infiltration on the prognosis of esophageal cancer and its value in pan-cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-02-06 Ziyu Liu, Zahra Zeinalzadeh, Tao Huang, Yingying Han, Lushan Peng, Dan Wang, Zongjiang Zhou, DIABATE Ousmane, Junpu Wang
Esophageal cancer, known for its high incidence and low five-year survival rate, poses significant treatment challenges. A key aspect of this challenge is the close link between mitochondria and resistance to chemoradiotherapy (CRT). Currently, there is a scarcity of biomarkers for predicting CRT response and prognosis in esophageal cancer. Our study addresses this gap by developing a prognostic model
-
Development and validation of a deep learning signature for predicting lymphovascular invasion and survival outcomes in clinical stage IA lung adenocarcinoma: A multicenter retrospective cohort study Transl. Oncol. (IF 5.0) Pub Date : 2024-02-06 Kunfeng Liu, Xiaofeng Lin, Xiaojuan Chen, Biyun Chen, Sheng Li, Kunwei Li, Huai Chen, Li Li
The presence of lymphovascular invasion (LVI) influences the management and outcomes of patients with clinical stage IA lung adenocarcinoma. The objective was the development of a deep learning (DL) signature for the prediction of LVI and stratification of prognosis. A total of 2077 patients from three centers were retrospectively enrolled and divided into a training set ( = 1515), an internal validation
-
Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture Transl. Oncol. (IF 5.0) Pub Date : 2024-02-05 Joseph Zenga, Musaddiq Awan, Anne Frei, Jamie Foeckler, Rachel Kuehn, Oscar Villareal Espinosa, Jennifer Bruening, Becky Massey, Stuart Wong, Aditya Shreenivas, Monica Shukla, Julia Kasprzak, Yunguang Sun, Md Shaheduzzaman, Fanghong Chen, Tyce Kearl, Heather A. Himburg
[Display omitted]
-
ARID5A stabilizes Indoleamine 2,3-dioxygenase expression and enhances CAR T cell exhaustion in colorectal cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-02-04 Dandan Wu, Guijun Wang, Shuang Wen, Xian Liu, Qiang He
Resistance to chimeric antigen receptor (CAR) T-cell therapy remains a significant challenge in the treatment of solid tumors. This resistance is attributed to various factors, including antigen loss, immunosuppressive tumor microenvironment, and upregulated checkpoint molecules. Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that promotes immune escape in tumors. In this study
-
Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-03 Martina Borcinova, Robin Bartolini, Lily Koumbas Foley, Vojtech Novak, Pavla Taborska, Dmitry Stakheev, Michal Rataj, Daniel Smrz, Martina Fialova, Jaromir Hacek, Martin Komarc, Stepan Vesely, Marek Babjuk, Ilja Striz, Jirina Bartunkova, Tomas Buchler, Zuzana Ozaniak Strizova
-
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-02-02 Mahlatse C.M. Kgokolo, Nonkululeko Z. Malinga, Helen C. Steel, Pieter W.A. Meyer, Teresa Smit, Ronald Anderson, Bernardo L. Rapoport
The current study compared the levels and possible associations between systemic soluble immune checkpoints (sICPs, = 17) and a group of humoral modulators of immune suppressor cells ( = 7) in a cohort of patients with basal cell carcinoma (BCC, = 40) and a group of healthy control subjects ( = 20).
-
Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment Transl. Oncol. (IF 5.0) Pub Date : 2024-02-02 Michael E. Egger, Evan Alexander, Tracy Van Meter, Maiying Kong, Aye Aye Maung, Roland Valdes, Melissa Barousse Hall, Mark W. Linder
Radiographic imaging is the current standard for monitoring progression of tumor-burden and therapeutic resistance in patients with metastatic melanoma. Plasma circulating tumor DNA (ctDNA) has shown promise as a survelience tool, but longitudinal data on the dynamics between plasma ctDNA concentrations and radiographic imaging is lacking. We evaluated the relationship between longitudinal radiographic
-
A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center Transl. Oncol. (IF 5.0) Pub Date : 2024-02-02 Hui Zheng, Jingjing Chen, Jimiao Huang, Huan Yi, Shaoyu Zhang, Xiangqin Zheng
Currently, there is a lack of prognostic evaluation methods for non-serous epithelial ovarian cancer (EOC). We collected patients with non-serous EOC diagnosed between 2010 and 2017 from the Surveillance, Epidemiology, and End Results (SEER) database into a training cohort ( = 2078) and an internal validation cohort ( = 891). Meanwhile, patients meeting the criteria were screened from the Fujian Provincial
-
PARVB promotes malignant melanoma progression and is enhanced by hypoxic conditions Transl. Oncol. (IF 5.0) Pub Date : 2024-02-01 Ting Wang, Zhiqiang Wu, Yifeng Bi, Yao Wang, Chenglong Zhao, Haitao Sun, Zhipeng Wu, Zhen Tan, Hao Zhang, Haifeng Wei, Wangjun Yan
Beta-Parvin (PARVB) is an actin-binding protein with functionality in extracellular matrix binding. Recent studies suggest its potential as a biomarker for various cancers, given its role in governing several malignancies. Yet, its involvement and modulatory mechanisms in malignant melanoma remain under-explored. In this research, we undertook a comprehensive pan-cancer analysis centered on PARVB.
-
The role of tertiary lymphoid structure and B cells in nasopharyngeal carcinoma: Based on bioinformatics and experimental verification Transl. Oncol. (IF 5.0) Pub Date : 2024-01-31 Chujun Chen, Yan Zhang, Xiaoting Wu, Juan Shen
Transcriptomic characteristics and prognosis of tertiary lymphoid structures (TLS) and infiltrating B cells in nasopharyngeal carcinoma (NPC) remain unclear. Here, NPC transcriptomic data and clinical samples were used to investigate the role of infiltrating B cells and TLS in NPC. We investigated the gene expression and infiltrating immune cells of NPC patients and further investigated the clinical
-
Small molecule agents for triple negative breast cancer: Current status and future prospects Transl. Oncol. (IF 5.0) Pub Date : 2024-01-29 Yan Ou, Mengchao Wang, Qian Xu, Binxu Sun, Yingjie Jia
-
Identification of HSPD1 as a novel invasive biomarker associated with mitophagy in pituitary adenomas Transl. Oncol. (IF 5.0) Pub Date : 2024-01-29 Yu Zhang, Xin Ma, Congyu Liu, Zhixu Bie, Gemingtian Liu, Pinan Liu, Zhijun Yang
Background The crucial role of mitophagy in tumor progression has been recognized. Therefore, our study aimed to investigate the potential correlation between pituitary adenoma invasiveness and the mitophagy processes. Methods In this study, we used transcriptomics of postoperative tissue from 32 patients and quantitative proteomics of 19 patients to screen for mitophagy-related invasion genes in pituitary
-
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression Transl. Oncol. (IF 5.0) Pub Date : 2024-01-29 Marzia Del Re, Giovanna Irene Luculli, Iacopo Petrini, Andrea Sbrana, Vieri Scotti, Diego de Miguel Perez, Lorenzo Livi, Stefania Crucitta, Mauro Iannopollo, Francesca Mazzoni, Martina Ruglioni, Carmelo Tibaldi, Emanuela Olmetto, Irene Stasi, Editta Baldini, Giacomo Allegrini, Lorenzo Antonuzzo, Franco Morelli, Andrea Pierini, Nicola Panzeri, Romano Danesi
Background The present study evaluates the utility of NGS analysis of circulating free DNA (cfDNA), which incorporates small amounts of tumor DNA (ctDNA), at diagnosis or at disease progression (PD) in NSCLC patients. Methods Comprehensive genomic profiling on cfDNA by NGS were performed in NSCLC patients at diagnosis (if tissue was unavailable/insufficient) or at PD to investigate potential druggable
-
Pan-cancer analysis of ABCC1 as a potential prognostic and immunological biomarker Transl. Oncol. (IF 5.0) Pub Date : 2024-01-29 Tiantian Wang, Dean Rao, Chenan Fu, Yiming Luo, Junli Lu, Huifang Liang, Limin Xia, Wenjie Huang
ABCC1 belongs to the ATP-binding cassette (ABC) superfamily, which encompasses a total of 48 constituent members. ABCC1 has been shown to be associated with the growth, progression, and drug resistance of various types of cancer. However, the impact of ABCC1 on cancer immune infiltration and pan-cancer prognosis has been rarely studied. Our comprehensive pan-cancer analysis unveiled elevated ABCC1
-
Assessment of salivary miRNA, clinical, and demographic characterization in colorectal cancer diagnosis Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 Maryam Koopaie, Soheila Manifar, Mona Mohammad Talebi, Sajad Kolahdooz, Amirnader Emami Razavi, Mansour Davoudi, Sara Pourshahidi
-
Lysosomal alkalinization in nutrient restricted cancer cells activates cytoskeletal rearrangement to enhance partial epithelial to mesenchymal transition Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 H. Hazal Hüsnügil, Aliye Ezgi Güleç Taşkıran, Ismail Güderer, Leman Nur Nehri, Göksu Oral, Nazlı Şevval Menemenli, Özün Özcan, Ariana Noghreh, Aytekin Akyol, Sreeparna Banerjee
-
Identification and validation of stemness-based and ferroptosis-related molecular clusters in pancreatic ductal adenocarcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 Shiye Ruan, Hailiang Wang, Zhongyan Zhang, Qian Yan, Yubin Chen, Jinwei Cui, Shanzhou Huang, Qi Zhou, Chuanzhao Zhang, Baohua Hou
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with an extremely poor prognosis. Cancer stem cells (CSCs) are considered to be responsible for the poor survival, recurrence and therapy resistance of PDAC. Ferroptosis plays a crucial role in the sustain and survival of CSCs. Here, we employed a rigorous evaluation of multiple datasets to identify a novel stemness-based and ferroptosis-related
-
BRMS1L confers anticancer activity in non-small cell lung cancer by transcriptionally inducing a redox imbalance in the GPX2-ROS pathway Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 Penglong Cao, Juebin Gu, Mulin Liu, Yingxin Wang, Mingying Chen, Yizhu Jiang, Xiaoyan Wang, Siqi Zhu, Xue Gao, Shijun Li
Low expression levels of breast cancer metastasis suppressor 1 like (BRMS1L) have been associated with the growth of cancer cells. However, the mechanisms underlying the role of BRMS1L as an antitumour transcription factor in the progression of NSCLC have not been explored. Herein, we reveal that BRMS1L plays a key role as a tumour suppressor in inhibiting NSCLC proliferation and metastasis. Mechanistically
-
Increased heterogeneity in expression of genes associated with cancer progression and drug resistance Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 Anwesha Bose, Subhasis Datta, Rakesh Mandal, Upasana Ray, Riddhiman Dhar
-
Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 Min Yan, Ronghao Yang, Qi Li, Chenjie Wang, Jiali Chen, Zhenying Wu, Han Li, Juan Fan
Background The progression and metastasis of tumors are typically accompanied by angiogenesis. Crucially, vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) play a significant role in tumor-associated angiogenesis. In this study, the aim was to investigate the antitumor effect of combining bevacizumab (Bev) with anlotinib (An) on colorectal cancer (CRC). Methods The CCK-8 assay, EdU
-
High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis Transl. Oncol. (IF 5.0) Pub Date : 2024-01-22 Dongze Zhang, Haitao Huang, Xin Gao, Gehua Yu, Xueguang Zhang, Haiyan Jin, Ruyan Xu, Zhenxin Wang, Guangbo Zhang
Monocyte/macrophages constitute a significant population of tumor-infiltrating immune cells and play a crucial role in tumor growth, invasion, and metastasis. B7-H3, has immune regulatory functions, however, it is unclear whether B7-H3 expressed on monocyte/macrophages plays a significance role in tumor progression. We found B7-H3 was high-expressed on monocyte/macrophages in tumor microenvironment
-
Multi-omics comprehensive analyses of programmed cell death patterns to regulate the immune characteristics of head and neck squamous cell carcinoma Transl. Oncol. (IF 5.0) Pub Date : 2024-01-18 Yi Jin, Siwei Huang, Hongyu Zhou, Zhanwang Wang, Yonghong Zhou
-
m6A demethylase ALKBH5 maintains stemness of intrahepatic cholangiocarcinoma by sustaining BUB1B expression and cell proliferation Transl. Oncol. (IF 5.0) Pub Date : 2024-01-18 Yuan Gao, Miao Yu, Zengyuan Liu, Yi Liu, Zhijun Kong, Chunfu Zhu, Xihu Qin, Yan Li, Liming Tang
-
Tissue contexture determines the pattern and density of tumor-infiltrating immune cells in HPV-associated squamous cell carcinomas of oropharynx and uterine cervix Transl. Oncol. (IF 5.0) Pub Date : 2024-01-18 Lucie Pavelková, Eliška Táborská, Linn A. Syding, Klára Plačková, Ekaterina Simonova, Kamila Hladíková, Michal Hensler, Jan Laco, Vladimír Koucký, Michal Zábrodský, Jan Bouček, Marek Grega, Kateřina Rozkošová, Hana Vošmiková, Michael J. Halaška, Lukáš Rob, Ivan Práznovec, Miroslav Hodek, Milan Vošmik, Petr Čelakovský, Anna Fialová
The profile of the antitumor immune response is an important factor determining patient clinical outcome. However, the influence of the tissue contexture on the composition of the tumor microenvironments of virally induced tumors is not clearly understood. Therefore, we analyzed the immune landscape of two HPV-associated malignancies: oropharyngeal squamous cell carcinoma (OPSCC) and squamous cell
-
CXCL16 promotes tumor metastasis by regulating angiogenesis in the tumor micro-environment of BRAF V600E mutant colorectal cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-01-16 Weihao Deng, Xiaoxia Liu, Shuhui Huang, Zhijie Wu, Fichera Alessandro, Qingfeng Lin, Zonglu Cai, Zitong Zhang, Yan Huang, Hui Wang, Zixu Yuan
Patients of colorectal cancer (CRC) with BRAF V600E mutation obtain poor prognosis. This study aimed to explore the role and mechanism of BRAF V600E mutation in angiogenesis of tumor micro-environment (TME). It has been reported that CXCL16 expression in TME is closely related to BRAF mutation. Clinicopathological features of CRC with BRAF V600E mutant or wild type were collected in this study. Immunohistochemistry
-
Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors Transl. Oncol. (IF 5.0) Pub Date : 2024-01-12 Maria Diaz, Sofia Chudsky, Elena Pentsova, Alexandra M. Miller
-
Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways Transl. Oncol. (IF 5.0) Pub Date : 2024-01-06 Silvia García-Roman, Mónica Garzón-Ibáñez, Jordi Bertrán-Alamillo, Núria Jordana-Ariza, Ana Giménez-Capitán, Beatriz García-Peláez, Marta Vives-Usano, Jordi Codony-Servat, Erik d'Hondt, Rafael Rosell, Miguel Ángel Molina-Vila
Background The EGFR pathway is involved in intrinsic and acquired resistance to a wide variety of targeted therapies in cancer. Vaccination represents an alternative to the administration of anti-EGFR monoclonal antibodies, such as cetuximab or panitumumab. Here, we tested if anti-EGF antibodies generated by vaccination (anti-EGF VacAbs) could potentiate the activity of drugs targeting the ERK/MAPK
-
The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae Transl. Oncol. (IF 5.0) Pub Date : 2024-01-06 Anette Lodvir Hemsing, Jan-Lukas Førde, Håkon Reikvam, Lars Herfindal
Ras-related C3 botulinum toxin substrate 1 (Rac1) is a GTPase implicated in cell migration and homing of hematopoietic cells to the hematopoietic niche, and is commonly overexpressed in acute myeloid leukemia (AML). This can lead to quiescence of leukemic blasts in the niche and reduced response to therapy. We investigated the Rac1 inhibitor EHop-016 on AML by assessing its effects on MOLM-13 cells
-
Heterogeneity of computational pathomic signature predicts drug resistance and intra-tumor heterogeneity of ovarian cancer Transl. Oncol. (IF 5.0) Pub Date : 2024-01-06 Qiuli Zhu, Hua Dai, Feng Qiu, Weiming Lou, Xin Wang, Libin Deng, Chao Shi
Background Chemotherapy resistance is the main cause of ovarian cancer progression and even death. However, there are no clear indicators for predicting the risk of drug resistance in patients. Intra-tumor heterogeneity (ITH) is one of the characteristics of malignant tumors, which is associated with the treatment and prognosis of tumors. Accordingly, our study aims to investigate the correlation between
-
CK1δ/ε inhibition induces ULK1-mediated autophagy in tumorigenesis Transl. Oncol. (IF 5.0) Pub Date : 2024-01-06 Vivian Weiwen Xue, Shanshan Liu, Qi Sun, Jiong Ning, Huan Li, Weilan Wang, Sapna Sayed, Xibao Zhao, Li Fu, Desheng Lu
Introduction Autophagy is an important mechanism of cell homeostasis maintenance. As essential serine/threonine-protein kinases, casein kinase I family members affect tumorigenesis by regulating a variety of cellular progression. However, the mechanism by which they regulate autophagy remains unclear. Materials and methods We silenced CK1δ/ε in cancer cells and observed cell morphology, the expression